UPS
REGN icon

UHLMANN PRICE SECURITIES’s Regeneron Pharmaceuticals REGN Stock Holding History

UHLMANN PRICE SECURITIES’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$309K Buy
496
+60
+14% +$40.8K 0.01% 206
2026
Q1 		$323K Buy
+436
New +$334K 0.02% 179

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

UHLMANN PRICE SECURITIES's REGN Position: Q2 2026 in Review

UHLMANN PRICE SECURITIES increased its Regeneron Pharmaceuticals (REGN) stake by 14% in Q2 2026, buying an estimated $40.8K and bringing the position to 496 shares worth $309K. The position accounts for 0.01% of the portfolio, ranked #206.

UHLMANN PRICE SECURITIES first reported a position in REGN in Q1 2026 and has held it in 2 quarters since. The position peaked at $323K in Q1 2026. 1,340 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • UHLMANN PRICE SECURITIES held 496 shares of Regeneron Pharmaceuticals worth $309K as of Q2 2026.
  • UHLMANN PRICE SECURITIES bought 60 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $40.8K.
  • Regeneron Pharmaceuticals made up 0.01% of UHLMANN PRICE SECURITIES's portfolio in Q2 2026, its #206 holding.
  • UHLMANN PRICE SECURITIES first reported a position in Regeneron Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • UHLMANN PRICE SECURITIES's Regeneron Pharmaceuticals position peaked at $323K in Q1 2026.
  • 1,340 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on UHLMANN PRICE SECURITIES's 13F filing for Q2 2026, filed 24 Jul 2026.